FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to immunology, and can be used in medicine for anticancer therapy. There are described embodiments of antibodies and their antigen-binding fragments binding with human 4-1BB, also called CD137 or TNFRSF9. There are described embodiments of a pharmaceutical composition for reducing tumor growth or for treating cancer in a subject, as well as methods for reducing tumor growth or treating cancer in a subject, using versions of antibodies or antigen-binding fragments thereof in a therapeutically effective amount. described is a method of treating cancer with using a combination of the antibody and an immunotherapeutic agent.
EFFECT: invention provides preparing new agonist antibodies to human 4-1BB.
14 cl, 8 dwg, 11 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| ANTIBODIES TARGETING A RECEPTOR BOUND TO G-PROTEINS, AND METHODS FOR USE THEREOF | 2015 |
|
RU2725819C2 |
| ANTIBODIES FOR TREATMENT OF HEPATITIS B INFECTION AND RELATED DISEASES | 2018 |
|
RU2765878C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| ANTI-GM-CSF ANTIBODIES AND USING THEM | 2006 |
|
RU2447085C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
| IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
